Reference number(s)
5664-A

Exception Criteria
Preventive Services Statins
Zero Copay Exception

Products Referenced by this Document

Low And Moderate Intensity Statins

Brand Name	Generic Name
Low and Moderate Intensity Statins (Brand Only)	Not applicable (Brand Only)

High Intensity Statins

Brand Name	Generic Name	Dosage
Crestor	rosuvastatin	20mg, 40mg only
Ezallor	rosuvastatin	20mg, 40mg only
Lipitor	atorvastatin	40mg, 80mg only
Zocor	simvastatin	80mg only

Intent

The intent of the criteria is to allow the member to receive a brand low/moderate intensity statin or brand/generic high intensity statin for a $0 member cost share when using for the primary prevention of cardiovascular disease for adults aged 40 to 75 years when the drug is determined to be medically necessary for the member by the member's attending health care provider. NOTE: The U.S. Preventive Services Task Force recommendation does not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (4.92 mmol/L) or known familial hypercholesterolemia. NOTE:

Initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.

Coverage Criteria

Authorization may be granted for the requested drug at $0 member cost share when the following criteria are met:

- The attending health care provider has determined the requested drug to be medically necessary for the primary prevention of cardiovascular disease in a patient 40 to 75 years of age, who has one or more cardiovascular risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking), and an estimated 10-year risk of a cardiovascular event of 10 percent or greater

[Note: The U.S. Preventive Services Task Force recommendation does not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (4.92 mmol/L) or known familial hypercholesterolemia.]

[Note: Initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.]

Duration of Approval (DOA)

- 5664-A: DOA: 36 months